---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038329"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:38:31.167990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway

## Summary
- Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.
- Cash, investments $892.1M, down $127.7M sequentially; runway into mid-2027.
- ECLIPSE registrational program for chronic hepatitis Delta fully underway; ECLIPSE 2 and 3 enrolling patients.
- First patient dosed in Phase 1 of VIR-5525 (EGFR-targeting PRO-XTEN T-cell engager); three PRO-XTEN Phase 1 studies ongoing.
- R&D expenses $97.5M (down from $105.1M) reflecting restructuring savings partially offset by clinical costs.

## SEC filing metadata
- accession: 0001628280-25-038329
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828025038329/0001628280-25-038329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828025038329/vir-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038329
- JSON: https://secwatch.observer/filing/0001628280-25-038329.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.